Archive · 25 Nov 2025
Zydus Lifesciences Receives FDA Approval for BP Drug
Zydus Lifesciences, a drug company, got permission from the US FDA to sell a medicine called verapamil hydrochloride.
This medicine helps people with high blood pressure.
The company makes this medicine in India and has been selling it in the US, where it made $24.5 million last year.
Zydus also shared its recent financial results, showing that it made more money this year compared to last year.
The company's stock price went up a little bit on the day this news came out.
Zydus Lifesciences received final FDA approval for verapamil hydrochloride extended-release tablets in 120 mg, 180 mg, and 240 mg strengths.
The drug is used to lower high blood pressure and reduce the risk of cardiovascular conditions like strokes and heart attacks.
The product will be manufactured at Zydus's facility in Baddi, Himachal Pradesh.
Zydus reported a 39% year-on-year increase in consolidated net profit to ₹1,259 crore for the second quarter.
The company's revenue for the quarter climbed 17% year-on-year to ₹6,123 crore, with strong performance in US and India formulations businesses.
- Who
- Zydus Lifesciences Ltd
- What
- Received final FDA approval for verapamil hydrochloride extended-release tablets
- When
- November 25, 2025
- Where
- United States (FDA approval), manufactured in Baddi, Himachal Pradesh
- Why
- To lower high blood pressure and reduce the risk of serious cardiovascular conditions
- Company
- Zydus Lifesciences Ltd
- Approval Received
- Final FDA approval for verapamil hydrochloride extended-release tablets
- Strengths Approved
- 120 mg, 180 mg, 240 mg
- Manufacturing Location
- Baddi, Himachal Pradesh
- Total FDA Approvals
- 428
- Total ANDAs Filed
- 487
- Net Profit (Q2)
- ₹1,259 crore (39% YoY growth)
- Revenue (Q2)
- ₹6,123 crore (17% YoY growth)
- EBITDA (Q2)
- ₹2,014 crore (38% YoY growth)
- Share Price (BSE)
- ₹927.50 (as of November 25)